Hypertension remains one of the leading health issues; however, the awareness and control remain limited, with approximately 1.4 billion people affected by hypertension, yet only one in five has the condition effectively controlled. Despite the availability of effective treatments, knowledge and awareness remain limited. Angiotensin II receptor blockers (ARBs) are widely used antihypertensive medications because of their efficacy and safety profiles. Among these, Olmesartan Medoxomil has emerged